SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Starkhammar Hans 1948 )
 

Search: WFRF:(Starkhammar Hans 1948 ) > Short-time infusion...

  • Pfeiffer, P (author)

Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil

  • Article/chapterEnglish2006

Publisher, publication year, extent ...

  • Elsevier BV,2006
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-36136
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-36136URI
  • https://doi.org/10.1093/annonc/mdj060DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-25381URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1932412URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established. Oxaliplatin induces acute, cold-induced neuropathy in most patients. The incidence is claimed to be infusion rate-dependent and therefore a 2-h infusion is recommended. Patients and methods: For practical and economic reasons, but also for patient's convenience, we performed a phase II study to examine XELOX30 (capecitabine 1000 mg/m2 orally twice daily on days 1-14 and oxaliplatin 130 mg/m2 as a 30 min infusion on day 1) in patients with ACRC resistant to irinotecan. In addition the pharmacokinetics of oxaliplatin was studied. Results: From November 2002 to September 2003, 70 patients with ACRC were treated with XELOX30. Median age was 62 (range 33-74 years) years and median performance status was 1 (range 0-2). The median number of courses was four (range 1-12) and median cumulative dose of oxaliplatin was 530 (range 125-1560) mg/m2. The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2). White blood cell count (WBC) and performance status were significantly correlated to TTP. Neurotoxicity was moderate: grade 1 56%, grade 2 17% and grade 3 6%. Other grade 3 toxicities were nausea/ vomiting 9%, diarrhoea 14% and PPE 8%. The maximum blood concentration and total body clearance of oxaliplatin was higher than previously reported in studies examining 2-h infusions, but the volume of distribution and terminal half-life was in close agreement with previous results. Conclusion: XELOX30 is a very convenient second-line regimen in ACRC with an activity and safety profile similar to other oxaliplatin schedules. © 2005 European Society for Medical Oncology.

Subject headings and genre

  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sörbye, H (author)
  • Ehrsson, H (author)
  • Fokstuen, T (author)
  • Mortensen, JP (author)
  • Baltesgard, L (author)
  • Tveit, KM (author)
  • Ögreid, D (author)
  • Starkhammar, Hans,1948-Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US(Swepub:liu)hanst87 (author)
  • Wallin, I (author)
  • Qvortrup, C (author)
  • Glimelius, BKarolinska Institutet,Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi (author)
  • Linköpings universitetHälsouniversitetet (creator_code:org_t)

Related titles

  • In:Annals of Oncology: Elsevier BV17:2, s. 252-2580923-75341569-8041

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view